The current price-to-earnings ratio of NEO can't be determined, as the TTM EPS of -$0.62 is negative. Neogenomics's last PE ratio on record was 114.86 in September 2021.
The mean historical PE ratio of Neogenomics over the last ten years is 723.32. In the past ten years, NEO's PE ratio reached its highest point in the Jun 2019 quarter at 2,194, with a price of $21.94 and an EPS of $0.01. The Jun 2021 quarter saw the lowest point at 74.05, with a price of $45.17 and an EPS of $0.61.
Maximum annual increase: 268.13% in 2020
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | N/A | N/A | $16.48 | -$0.62 |
2023 | N/A | N/A | $16.18 | -$0.7 |
2022 | N/A | N/A | $9.24 | -$1.16 |
2021 | N/A | N/A | $34.12 | -$0.07 |
2020 | 1,346 | 268.13% | $53.84 | $0.04 |
2019 | 365.63 | 102.97% | $29.25 | $0.08 |
2018 | 180.14 | N/A | $12.61 | $0.07 |
2017 | N/A | N/A | $8.86 | -$0.14 |
2016 | N/A | N/A | $8.57 | -$0.4 |
2015 | N/A | N/A | $7.87 | -$0.04 |
2014 | 208.5 | 130.39% | $4.17 | $0.02 |
2013 | 90.5 | N/A | $3.62 | $0.04 |
2012 | N/A | N/A | $2.48 | $0 |
2011 | N/A | N/A | $1.4 | -$0.03 |
2010 | N/A | N/A | $1.3 | -$0.09 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | N/A | N/A | $16.48 | -$0.62 |
Sep 2024 | N/A | N/A | $14.75 | -$0.61 |
Jun 2024 | N/A | N/A | $13.87 | -$0.62 |
Mar 2024 | N/A | N/A | $15.72 | -$0.66 |
Dec 2023 | N/A | N/A | $16.18 | -$0.7 |
Sep 2023 | N/A | N/A | $12.3 | -$0.77 |
Jun 2023 | N/A | N/A | $16.07 | -$0.92 |
Mar 2023 | N/A | N/A | $17.41 | -$1.01 |
Dec 2022 | N/A | N/A | $9.24 | -$1.16 |
Sep 2022 | N/A | N/A | $8.61 | -$1.33 |
Jun 2022 | N/A | N/A | $8.15 | -$1.2 |
Mar 2022 | N/A | N/A | $12.15 | -$0.28 |
Dec 2021 | N/A | N/A | $34.12 | -$0.07 |
Sep 2021 | 114.86 | 55.11% | $48.24 | $0.42 |
Jun 2021 | 74.05 | N/A | $45.17 | $0.61 |
Stock name | PE ratio | Market cap |
---|---|---|
DGX Quest Diagnostics Inc | 22.14 | $19.11B |
LH Laboratory Corp Of America Holdings | 47.05 | $20.9B |
RDNT RadNet Inc | N/A | $4.4B |
ENZ Enzo Biochem Inc | N/A | $26.98M |
NEO Neogenomics Inc | N/A | $1.43B |
The current price to earnings ratio of NEO can't be calculated, as its EPS of -$0.62 is negative.
In the last ten years, the Jun 2019 quarter recorded the highest quarterly PE ratio at 2,194.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.